Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer

INTRODUCTION: This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer. METHODS: Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Thorac Oncol
Glavni autori: Choong, Nicholas W., Mauer, Ann M., Haraf, Daniel J., Lester, Eric, Hoffman, Philip C., Kozloff, Mark, Lin, Shang, Dancey, Janet E., Szeto, Livia, Grushko, Tatyana, Olopade, Olufunmilayo I., Salgia, Ravi, Vokes, Everett E.
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535721/
https://ncbi.nlm.nih.gov/pubmed/18758303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818396a4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items